Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Forest Vows To Double Pipeline Potential

Oct 21 2008

• By Emily Hayes

Related Content

Risk Info Should Be In Ad, Not Attached Label, FDA Says In Bystolic Ad Letter

Sep 15 2008

FDA Puts Off Forest’s Fibromyalgia Drug Milnacipran

Oct 20 2008

Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market

Dec 18 2007

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window